Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novo And Langer Lab Pursue Oral Peptides

by Lisa M. Jarvis
September 14, 2015 | A version of this story appeared in Volume 93, Issue 36

Novo Nordisk will work with MIT professor Robert S. Langer to develop drug delivery devices for peptides. Working with Harvard biomedical engineer Giovanni Traverso, the team will look to deliver peptides, which are normally injected or administered intravenously, in a pill. The researchers must prevent the drug from degrading before it reaches its target, limit the variability of absorption, and find a cost-effective way to manufacture the product. Novo will fund research positions in Langer’s lab over the three years of the pact.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.